Category Archives: Cancer

Eric Lefkofsky and the Tempus Solution to Cancer Care

Cancer is one of the most terrifying diagnosis that can be handed down to a patient sitting within their doctors office. Medical research is an industry unto itself and bright minds around the world are focused on finding a way to make that diagnosis just a little less intimidating. Eric Lefkofsky is one of the brighter tech minds coming out of Chicago in recent decades. He’s established himself as someone who can innovate within the specialty niche of data focused precision medicine. This specialty brought Lefkofsky to found his latest company, Tempus.

The healthcare industry is an industry that is always seemingly on the cutting edge of something new — and it’s important that it is. In order for lives to be saved, technological innovations have to be coming through the door at a record pace. A few years back the introduction of Electronic Health Records, otherwise known as EHRs, gave life to the industry. Now, years later, we know that they aren’t enough. Medical records are still notoriously sloppy and hard to corroborate between clinics and nowhere is this more apparent than within the realm of cancer-care. This is the niche that Tempus is diving into and this is the service that Lefkofsky wants to remedy.

Tempus is Eric Lefkofsky’s latest start up and his mission statement is to fundamentally change the way that cancer care and cancer research is approached. Tempus is an analytical piece of software that looks at a patient’s molecular and clinical data before streamlining the process into a digital interface. This data is primarily focused on genomic information. This data is then accessible by cancer care clinics and hospitals all around the country, at least those that interface with the Tempus system. Lefkofsky’s plan was to introduce a new operating system, sort of like a digital blanket, that lay directly over top the already implemented EHRs.

Lefkofsky is focused on the development of genome sequencing because he believes it to be the key to unlock cancer research. Lefkofsky believes, and medical research backs him up, that the human gene has the information required to find more effective paths to treatment for cancer.

To know more visit @:

“Dr. Clay Siegall – Fervently Fighting Cancer”

Located in Washington State’s Bothell Cascade Business Park, you will discover the headquarters of Seattle’s Genetics, Inc., a biotechnology company with a passion for treating cancer, which was established in 1998.

Within one of these buildings, you will find The Board’s President, Chief Executive Officer and Chairman, Dr. Clay Siegall.

Here you will find constant research in developing and manipulating antibodies, in which an immune response is triggered, weakening or destroying the antigens or toxins in the affected body.

This plan of action can result in Seattle Genetics becoming a major player in the pharmaceutical field.

With an estimated market value of $10 billion, along with 900 workers and the intention of adding 200 more in the future, this company rates as the biggest biotech institution in Washington State.

The primary drug for Seattle Genetics is Adcetris.

It is earmarked for treating Hodgkin’s disease, a condition in which there is an increase in the size of the lymph tissues and if the condition worsens, the liver and spleen might have issues as well.

Our rigorous research, if Adcetris prove to overcome cancer cells, this would be cutting-edge therapy and part of Oncologists first line of defense.

Of course, this would result in exponential profits in yearly sales.

This is only one of the eleven drugs Seattle Genetics have in their cancer-fighting arsenal.

Dr. Siegall is dedicated to transforming the company from biotech to a pharmaceutical enterprise.

He has also taken steps to delve into international marketing of the drugs, by opening a business in Switzerland, so Seattle Genetics can promote and distribute their own products.

Although the state of the economy and political climate might be baffling at times, Siegall remains positive about the progress of the company. He enjoys what he is doing and he does not get distracted, while advancing toward his goals.

Dr. Clay Siegall is the co-founder of Settle Genetics, Inc. With him at the helm, the company has produced a variety of cancer treatment medications, with their primary drug Adcetris getting advanced approval by the Federal Food and Drug Administration (FDA).

He received a Bachelor of Science from the University of Maryland and a Ph.D. in Genetics from Georgetown University.

Previously Siegall worked for other medical facilities including, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute.

While remembering the words of one of his previous mentors, in which he stated, “Don’t take no for an answer”, Dr. Clay Siegall continues to persevere in the fight against cancer.


Erik Lefkofsky sees the coming genomic revolution as a watershed moment in medicine

Eric Lefkofksy is a giant of the tech startup world. After having co-founded Groupon, a highly innovative firm that uses the power of volume purchasing to extend deep discounts to buyers, who are located all across the world, Lefkofsky has gone on to create a half-dozen other startups that have proven him as one of the top entrepreneurs in the country.

But in 2013, Lefkofsky’s wife received terrible news. She had been diagnosed with an advanced case of breast cancer and would need to begin aggressive treatment immediately. As shocked as Lefkofsky was at his wife’s sudden plight, he was even more taken aback by the apparently lackadaisical approach that the entire oncology profession apparently took towards the collation utilization of data. Lefkofksy noted that many of the oncologists, who were helping his wife fight to stay alive, had lower quality data to work with than many of the country’s truck drivers.

Fortunately, Lefkofsky’s wife made it through the ordeal fine and, today, is a cancer survivor. But one other good thing came from the Lefkofsky family’s cancer travails. In 2016, Eric Lefkofsky founded Tempus, an organization dedicated to bringing state-of-the-art data collection and analysis techniques to oncologists across the country.

Tempus uses many sources of data. These range from electronic medical records to high-level meta-studies of large research cohorts and everything in between. However, the most daunting source of new data for the company’s software solutions is the human genome itself. Today, it is not just possible but economically viable to sequence virtually anyone’s genome. This is a recent development and one that Lefkofsky says will only become cheaper and easier in the coming years.

With the vast trove of data that knowing full patient genomes can bring, Lefkofsky says that oncologists will be able to attain a level of granularity in their understanding of both cancer types treatment responses that has never before even been imagines.

They will be able to break patient cohorts into nearly infinite subgroups, tailor-making treatment regimens that are most likely to succeed for the individual patient, not a crudely defined group of 100,000 people.

Learn More: